Patients with Chronic Lymphocytic Leukemia Have a Very High Risk of Ineffective Response to the BNT162b2 Vaccine
Abstract
:1. Introduction
2. Materials and Methods
3. Results
4. Discussion
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Langerbeins, P.; Eichhorst, B. Immune Dysfunction in Patients with Chronic Lymphocytic Leukemia and Challenges during COVID-19 Pandemic. Acta Haematol. 2021, 144, 508–518. [Google Scholar] [CrossRef] [PubMed]
- Shadman, M.; Ujjani, C. Vaccinations in CLL: Implications for COVID-19. Blood 2021, 137, 144–146. [Google Scholar] [CrossRef] [PubMed]
- Scarfò, L.; Chatzikonstantinou, T.; Rigolin, G.M.; Quaresmini, G.; Motta, M.; Vitale, C.; Garcia-Marco, J.A.; Hernández-Rivas, J.; Mirás, F.; Baile, M.; et al. COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: A joint study by ERIC, the European Research Initiative on CLL, and CLL Campus. Leukemia 2020, 34, 2354–2363. [Google Scholar] [CrossRef] [PubMed]
- Chatzikonstantinou, T.; Kapetanakis, A.; Scarfò, L.; Karakatsoulis, G.; Allsup, D.; Cabrero, A.A.; Andres, M.; Antic, D.; Baile, M.; Baliakas, P.; et al. COVID-19 severity and mortality in patients with CLL: An update of the international ERIC and Campus CLL study. Leukemia 2021, 35, 3444–3454. [Google Scholar] [CrossRef] [PubMed]
- Teh, J.S.K.; Coussement, J.; Neoh, Z.C.; Spelman, T.; Lazarakis, S.; Slavin, M.A.; Teh, B.W. Immunogenicity of COVID-19 Vaccines in Patients with Hematological Malignancy: A Systematic Review and Meta-Analysis. Blood Adv. 2021. Available online: https://findanexpert.unimelb.edu.au/scholarlywork/1617888-immunogenicity-of-covid-19-vaccines-in-patients-with-hematological-malignancy--a-systematic-review-and-meta-analysis (accessed on 6 March 2022).
- Herishanu, Y.; Avivi, I.; Aharon, A.; Shefer, G.; Levi, S.; Bronstein, Y.; Morales, M.; Ziv-Baran, T.; Arbel, Y.S.; Scarfò, L.; et al. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. Blood 2021, 137, 3165–3173. [Google Scholar] [CrossRef]
- Bergman, P.; Blennow, O.; Hansson, L.; Mielke, S.; Nowak, P.; Chen, P.; Söderdahl, G.; Österborg, A.; Smith, C.I.E.; Wullimann, D.; et al. Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial. eBioMedicine 2021, 74, 103705. [Google Scholar] [CrossRef]
- Herishanu, Y.; Rahav, G.; Levi, S.; Braester, A.; Itchaki, G.; Bairey, O.; Dally, N.; Shvidel, L.; Ziv-Baran, T.; Polliack, A.; et al. Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination. Blood 2022, 139, 678–685. [Google Scholar] [CrossRef] [PubMed]
- Bagacean, C.; Letestu, R.; Al-Nawakil, C.; Brichler, S.; Lévy, V.; Sritharan, N.; Delmer, A.J.; Dartigeas, C.; Leblond, V.; Roos-Weil, D.; et al. Humoral response to mRNA anti–COVID-19 vaccines BNT162b2 and mRNA-1273 in patients with chronic lymphocytic leukemia. Blood Adv. 2022, 6, 207–211. [Google Scholar] [CrossRef]
- Šušol, O.; Hájková, B.; Zelená, H.; Hájek, R. Third dose of COVID-19 vaccine restores immune response in patients with haematological malignancies after loss of protective antibody titres. Br. J. Haematol. 2022, 197, 302–305. [Google Scholar] [CrossRef]
- Marlet, J.; Gatault, P.; Maakaroun, Z.; Longuet, H.; Stefic, K.; Handala, L.; Eymieux, S.; Gyan, E.; Dartigeas, C.; Gaudy-Graffin, C. Antibody Responses after a Third Dose of COVID-19 Vaccine in Kidney Transplant Recipients and Patients Treated for Chronic Lymphocytic Leukemia. Vaccines 2021, 9, 1055. [Google Scholar] [CrossRef] [PubMed]
- DiaSorin. LIAISON® SARS-CoV-2 TrimericS IgG Assay. Available online: https://artemisialab.it/wp-content/uploads/2021/03/liaisonr_sars-cov-2_trimerics_igg_assay_m0870004408_lr_digital.pdf (accessed on 1 February 2021).
- Thomas, S.J.; Moreira, E.D., Jr.; Kitchin, N.; Absalon, J.; Gurtman, A.; Lockhart, S.; Perez, J.L.; Pérez Marc, G.; Polack, F.P.; Zerbini, C.; et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months. N. Engl. J. Med. 2021, 385, 1761–1773. [Google Scholar] [CrossRef] [PubMed]
- Herzog Tzarfati, K.; Gutwein, O.; Apel, A.; Rahimi-Levene, N.; Sadovnik, M.; Harel, L.; Benveniste-Levkovitz, P.; Chaim, A.B.; Koren-Michowitz, M. BNT162b2 COVID-19 vaccine is significantly less effective in patients with hematologic malignancies. Am. J. Hematol. 2021, 96, 1195–1203. [Google Scholar] [CrossRef] [PubMed]
- Morawska, M. Reasons and consequences of COVID-19 vaccine failure in patients with chronic lymphocytic leukemia. Eur. J. Haematol. 2022, 108, 91–98. [Google Scholar] [CrossRef] [PubMed]
- Molica, S.; Giannarelli, D.; Lentini, M.; Zappala, D.; Mannella, A.; Loiacono, D.; Gianfelici, V.; Panduri, G.; Gariani, I.; Minchella, P.; et al. Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia: A Serologic and Cellular Study. Chemotherapy 2022, 67, 91–95. [Google Scholar] [CrossRef]
- Shen, Y.; Freeman, J.A.; Holland, J.; Solterbeck, A.; Naidu, K.; Soosapilla, A.; Downe, P.; Tang, C.; Kerridge, I.; Wallman, L.; et al. COVID-19 vaccine failure in chronic lymphocytic leukaemia and monoclonal B-lymphocytosis; humoural and cellular immunity. Br. J. Haematol. 2022, 197, 41–51. [Google Scholar] [CrossRef]
- Benjamini, O.; Rokach, L.; Itchaki, G.; Braester, A.; Shvidel, L.; Goldschmidt, N.; Shapira, S.; Dally, N.; Avigdor, A.; Rahav, G.; et al. Safety and efficacy of the BNT162b mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. Haematologica 2022, 107, 625–634. [Google Scholar]
- Roeker, L.E.; Knorr, D.A.; Thompson, M.C.; Nivar, M.; Lebowitz, S.; Peters, N.; Deonarine, I.; Momotaj, S.; Sharan, S.; Chanlatte, V.; et al. COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia. Leukemia 2021, 35, 2703–2705. [Google Scholar] [CrossRef]
- Ujjani, C.; Shadman, M.; Lynch, R.C.; Tu, B.; Stevenson, P.A.; Grainger, C.; Zhu, H.; Hill, J.A.; Huang, M.-L.; Nielsen, L.; et al. The impact of B-cell-directed therapy on SARS-CoV-2 vaccine efficacy in chronic lymphocytic leukaemia. Br. J. Haematol. 2022, 197, 306–309. [Google Scholar] [CrossRef]
- Kohn, M.; Delord, M.; Chbat, M.; Guemriche, A.; Merabet, F.; Roupie, A.-L.; Lombion, N.; Farhat, H.; Longval, T.; Cabannes-Hamy, A.; et al. A Third Anti-SARS-CoV-2 mRNA Dose Does Not Overcome the Pejorative Impact of Anti-CD20 Therapy and/or Low Immunoglobulin Levels in Patients with Lymphoma or Chronic Lymphocytic Leukemia. Haematologica 2021, 107, 1454. Available online: https://haematologica.org/article/view/haematol.2021.280026 (accessed on 13 July 2022). [CrossRef]
- Kotton, C.N. Belt and Suspenders: Vaccines and Tixagevimab/Cilgavimab for Prevention of COVID-19 in Immunocompromised Patients. Ann. Intern. Med. 2022, 175, 892–894. [Google Scholar] [CrossRef] [PubMed]
After 2nd Dose (n = 42) | After 3rd Dose (n = 27) | |||||
---|---|---|---|---|---|---|
Response to COVID-19 Vaccine | YES (n = 13) | NO (n = 29) | p | YES (n = 5) | NO (n = 22) | p |
Sex | ||||||
M | 4 | 13 | 0.39 | 5 | 10 | 0.03 |
F | 9 | 16 | 0 | 12 | ||
Previous Infections | ||||||
Yes | 5 | 13 | 0.69 | 0 | 11 | 0.04 |
No | 8 | 16 | 5 | 11 | ||
Age | 0.69 | 0.55 | ||||
>65 | 5 | 15 | 2 | 12 | ||
<65 | 8 | 14 | 3 | 10 | ||
CIRS * | 0.61 | 0.97 | ||||
<3 | 7 | 18 | 3 | 13 | ||
>3 | 6 | 11 | 2 | 9 | ||
Stage Binet | 0.28 | 0.99 | ||||
A | 3 | 2 | 0 | 0 | ||
B | 9 | 22 | 4 | 18 | ||
C | 1 | 5 | 1 | 4 | ||
N° of treatments | 0.18 | 0.99 | ||||
0–1 | 9 | 12 | 2 | 8 | ||
>1 | 4 | 17 | 3 | 14 | ||
Type of treatment | 0.41 | 0.45 | ||||
Naïve | 3 | 2 | - | - | ||
Other | 3 | 6 | 0 | 5 | ||
BTKi | 6 | 15 | 4 | 12 | ||
Ven-R | 1 | 6 | 1 | 5 | ||
Last rituximab | 0.18 | 0.12 | ||||
No rituximab | 7 | 10 | 2 | 3 | ||
>12months | 5 | 9 | 3 | 9 | ||
<12months | 1 | 10 | 0 | 10 | ||
PDN or IVIG * | 0.04 | 0.29 | ||||
No | 11 | 15 | 4 | 12 | ||
Yes | 2 | 14 | 1 | 10 | ||
ALC * | 0.89 | 0.38 | ||||
>5000/mm3 | 6 | 14 | 1 | 9 | ||
<5000/mm3 | 7 | 15 | 4 | 13 | ||
CD3 | 0.86 | 0.23 | ||||
>690/mm3 | 10 | 23 | 0 | 5 | ||
<690/mm3 | 3 | 6 | 5 | 17 | ||
CD4 | 0.68 | 0.30 | ||||
>410/mm3 | 11 | 23 | 0 | 4 | ||
<400/mm3 | 2 | 6 | 5 | 18 | ||
CD19 | 0.45 | 0.97 | ||||
>20/mm3 | 10 | 19 | 3 | 13 | ||
<20/mm3 | 3 | 10 | 2 | 9 | ||
NK | 0.10 | 0.73 | ||||
>300/mm3 | 7 | 8 | 1 | 16 | ||
<300/mm3 | 6 | 21 | 4 | 6 | ||
HGG * | 0.02 | |||||
No | 6 | 4 | 1 | 3 | 0.71 | |
Yes | 7 | 25 | 4 | 19 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Galitzia, A.; Barabino, L.; Murru, R.; Caocci, G.; Greco, M.; Angioni, G.; Mulas, O.; Oppi, S.; Massidda, S.; Costa, A.; et al. Patients with Chronic Lymphocytic Leukemia Have a Very High Risk of Ineffective Response to the BNT162b2 Vaccine. Vaccines 2022, 10, 1162. https://doi.org/10.3390/vaccines10071162
Galitzia A, Barabino L, Murru R, Caocci G, Greco M, Angioni G, Mulas O, Oppi S, Massidda S, Costa A, et al. Patients with Chronic Lymphocytic Leukemia Have a Very High Risk of Ineffective Response to the BNT162b2 Vaccine. Vaccines. 2022; 10(7):1162. https://doi.org/10.3390/vaccines10071162
Chicago/Turabian StyleGalitzia, Andrea, Luca Barabino, Roberta Murru, Giovanni Caocci, Marianna Greco, Giancarlo Angioni, Olga Mulas, Sara Oppi, Stefania Massidda, Alessandro Costa, and et al. 2022. "Patients with Chronic Lymphocytic Leukemia Have a Very High Risk of Ineffective Response to the BNT162b2 Vaccine" Vaccines 10, no. 7: 1162. https://doi.org/10.3390/vaccines10071162